SCHEMBL2646975

SCHEMBL2646975

Cc1ccc(C(=O)C=Cc2ccc(C3CCCCC3)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.67
POLB P06746 2/20 0.65
RAB9A P51151 2/20 0.65
MEN1 O00255 2/20 0.65
KMT2A Q03164 2/20 0.65
NPC1 O15118 1/20 0.65
BLM P54132 1/20 0.65
GPR35 Q9HC97 1/20 0.65
MAOB P27338 7/20 0.60
MAOA P21397 4/20 0.60
ALDH1A1 P00352 3/20 0.57
CYP1B1 Q16678 2/20 0.57
HPGD P15428 2/20 0.57
CYP3A4 P08684 1/20 0.57
CYP1A1 P04798 1/20 0.55
TRPM8 Q7Z2W7 1/20 0.53
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
PKM P14618 2/20 0.49
HTT P42858 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2665098 1.00 MAPT (0.67) MAPTPOLBRAB9AMEN1KMT2A
SCHEMBL2646972 1.00 MAPT (0.67) MAPTPOLBRAB9AMEN1KMT2A
SCHEMBL2665062 0.93 RAB9A (0.72) MAPTPOLBRAB9AMEN1KMT2A
SCHEMBL6918213 0.93 RAB9A (0.72) MAPTPOLBRAB9AMEN1KMT2A
SCHEMBL2647717 0.93 RAB9A (0.72) MAPTPOLBRAB9AMEN1KMT2A
SCHEMBL2647718 0.93 RAB9A (0.72) MAPTPOLBRAB9AMEN1KMT2A
SCHEMBL2665069 0.93 RAB9A (0.72) MAPTPOLBRAB9AMEN1KMT2A
SCHEMBL25196615 0.87 RAB9A (0.66) MAPTPOLBRAB9AMEN1KMT2A
SCHEMBL2648111 0.86 MEN1 (0.65) MAPTPOLBRAB9AMEN1KMT2A
SCHEMBL2665214 0.86 MEN1 (0.65) MAPTPOLBRAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1463715-A1 NOVEL GLUCAGON ANTAGONISTS NOVO NORDISK A/S (DK) 2004-10-06 EP disclosed
US-6762318-B2 CARBOXYLIC ACID OR TETRAZOLE DERIVATIZED SECONDARY AMIDES; ORAL ADMINISTRATION NOVO NORDISK A/S (DK) 2004-07-13 US disclosed
US-20030236292-A1 Stimulant releasing glucose from liver cells; antidiabetic agents PFIZER INC 2003-12-25 US disclosed
WO-2003048109-A1 NOVEL GLUCAGON ANTAGONISTS NOVO NORDISK A/S (DK) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236292-A1 Stimulant releasing glucose from liver cells; antidiabetic agents GPR119, GLP1R, GIPR MAPT 4668/4885POLB 4789/4885RAB9A 3070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.